ESR1

Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024

Retrieved on: 
목요일, 5월 30, 2024
McCormick Place, Fulvestrant, Safety, Breast cancer, MBC, Neoplasm, ASCO, ESR1, Society, Mutation, Therapy, Eli Lilly, Quality of life, Pharmaceutical industry

COLUMBUS, Ohio, May 30, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO).

Key Points: 
  • COLUMBUS, Ohio, May 30, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO).
  • ASCO 2024 will be held May 31-June 4, 2024, at McCormick Place in Chicago.
  • “Sermonix looks forward to updating our peers at ASCO 2024 about the progress of ELAINE-3, which is actively enrolling in the U.S., Canada, Europe and Israel,” said Dr. David Portman, Sermonix founder and chief executive officer.
  • We are excited to gain a greater understand of lasofoxifene’s potential as ELAINE-3 progresses, and hopefully bring it one important step closer to patients.”

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Retrieved on: 
목요일, 5월 30, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Incidence, DNA, Plasma, MBC, Circulating tumor DNA, Helmy Eltoukhy, PIK3CA, Neoplasm, Nucleic acid thermodynamics, Chinese, Interim, Biomarker, ASCO, ESR1, Society, Liquid biopsy, ABC, Annual general meeting, Medical imaging

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.
  • Additional studies will present data supporting the application of genomic and epigenomic biomarkers in areas such as minimal residual disease detection and cohort characterization.
  • “The robust data we present at ASCO will further demonstrate the important scientific and clinical developments in cancer care that are possible using liquid biopsy,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • For more information and updates from the meeting, follow Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth #28115.

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

Retrieved on: 
목요일, 5월 16, 2024
Patient, Progression-free survival, Fulvestrant, DNA, PROTAC, Febrile neutropenia, ARVN, HER2, Neutropenia, Fourth grade, PFS, Chimera, Safety, Cyclin-dependent kinase 4, Breast cancer, Congress, PFE, ESR1, Breast Cancer Research, Sarah Cannon Research Institute, Proteolysis, ESMO, CBR, Mutation, Pharmaceutical industry

NEW HAVEN, Conn. and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®). After six months of additional follow-up, these data are consistent with data presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2023, and show that vepdegestrant plus palbociclib continue to demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of prior therapy with locally advanced or metastatic ER positive (ER+)/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer. These updated data were presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.

Key Points: 
  • These updated data were presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.
  • “We're encouraged by the clinical activity and safety profile observed with vepdegestrant in combination with palbociclib in patients being treated for advanced ER+/HER2- breast cancer,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas.
  • Vepdegestrant is being co-developed by Arvinas and Pfizer and is being evaluated as a monotherapy in the second-line setting in the ongoing Phase 3 VERITAC-2 trial and in the first-line setting in combination with palbociclib in the ongoing study lead-in cohort of the Phase 3 VERITAC-3 trial.
  • The safety profile of vepdegestrant in combination with palbociclib was otherwise consistent with the profile of palbociclib and what has been observed in other clinical trials for vepdegestrant.

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

Retrieved on: 
수요일, 5월 15, 2024
Ribociclib, Half-life, Neutropenia, Pharmacokinetics, MTD, DNA, Plasma, Data, Toxicity, Index, Circulating tumor DNA, Safety, QT interval, Breast cancer, Neoplasm, Congress, Incidence, Partial, ESR1, Poster, Woman, Fatigue, CBR, Breast, Webcast, Pharmaceutical industry

These results, as of the data cut-off of March 13, 2024, will be presented on May 16, 2024, in a poster session at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany (ESMO Breast).

Key Points: 
  • These results, as of the data cut-off of March 13, 2024, will be presented on May 16, 2024, in a poster session at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany (ESMO Breast).
  • Palazestrant did not affect ribociclib drug exposure and ribociclib had no clinically meaningful effect on palazestrant drug exposure.
  • Findings from this study support the continued clinical development of palazestrant in combination with ribociclib for the first-line treatment of ER+/HER2- advanced or metastatic breast cancer.
  • Olema will host a webcast and conference call for analysts and investors to review the data being presented at ESMO Breast Cancer Annual Congress 2024 today, Wednesday, May 15, 2024, at 8:00 a.m.

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Retrieved on: 
목요일, 5월 23, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Traffic barrier, Patient, Everolimus, Toxicity, Clinical trial, University, Therapy, Safety, MBC, Cancer, ASCO, ESR1, Breast Cancer Research, Society, Sarah Cannon Research Institute, Multimedia, Brain, Medical imaging

Both the ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms observed in estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC) and improve patient outcomes through novel oral-oral combination treatment options.

Key Points: 
  • Both the ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms observed in estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC) and improve patient outcomes through novel oral-oral combination treatment options.
  • Data will be presented at the 2024 American Society of Clinical Oncology (ASCO), on June 2 from 9 a.m. to 12 p.m. CT.
  • Phase 2 for the combination of elacestrant and abemaciclib in ER+, HER2- metastatic breast cancer, irrespective of the metastatic site, is already ongoing.
  • “The data we are presenting at ASCO highlight elacestrant’s potential to further enhance patient outcomes when combined with other compounds.”

LaVoieHealthScience Awarded Best Pharma Product Launch at 2024 PRWeek Healthcare Awards

Retrieved on: 
수요일, 5월 22, 2024
Men, Research, Pharmaceutical, Oncology, Consumer, Public Relations, Investor Relations, Science, Marketing, Advertising, Biotechnology, Women, Communications, Health, Partnership, Organization, HER2, LHS, ESR1, Woman, Communication, Pharmaceutical industry

LaVoieHealthScience (LHS) is honored to be awarded with the prestigious title of "Best Pharma Product Launch (Non-OTC)” at this year’s PRWeek Healthcare Awards on May 21.

Key Points: 
  • LaVoieHealthScience (LHS) is honored to be awarded with the prestigious title of "Best Pharma Product Launch (Non-OTC)” at this year’s PRWeek Healthcare Awards on May 21.
  • The award-winning product launch, which focused on increasing visibility and on-label education of ORSERDU®, the first oral selective estrogen receptor modulator (SERD), approved for marketing in the US in January 2023.
  • The combined teams’ communication efforts highlight the impactful collaboration between Menarini Stemline and LaVoieHealthScience.
  • This recognition from PRWeek Healthcare Awards underscores our commitment to excellence in healthcare communications and our dedication to improving patient outcomes.

Caris Life Sciences to Showcase Extensive Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at ASCO 2024

Retrieved on: 
화요일, 5월 14, 2024
SCLC, Lung, Patient, Prognosis, Doctor of Philosophy, Immunotherapy, POA, PIWIL1, Diagnosis, Neoplasm, Endometrial cancer, TP53, Carcinoma, Breast cancer, NSCLC, Prostate, MBA, MD, Prostate cancer, Abstract, Research, Cancer, Biomarker, ASCO, CRC, Data analysis, Lung cancer, Medicine, ESR1, RNA, Society, Hepatocellular carcinoma, Genotype, Breast, NCI, HSD3B1, Annual general meeting, Medical imaging

IRVING, Texas, May 14, 2024 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™ (POA), will collectively present 41 studies across 19 tumor types at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting May 31 to June 4, 2024 (Booth #28001). The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • Through extensive sequencing and data analysis efforts, we're unlocking new avenues for tailored therapies to revolutionize cancer treatment."
  • (Abstract Number: 8088)
    Poster and abstract summaries highlighting the Caris research presented at ASCO 2024 will be available onsite at Caris' Booth 28001.
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

Retrieved on: 
월요일, 4월 22, 2024
FDA, PAM, ABC, Safety, Food, Prognosis, AKT, Patient, S6K, CMC, Acquisition, CSO, LSX, Breast cancer, ESR1, Pharmaceutical industry

Following a Type B meeting held on March 13, 2024, the U.S. Food and Drug Administration (FDA) provided Evexta Bio with valuable input on various aspects of rupitasertib development, including CMC, preclinical and clinical topics, enabling the company to proceed with the Phase 2 study in advanced breast cancer.

Key Points: 
  • Following a Type B meeting held on March 13, 2024, the U.S. Food and Drug Administration (FDA) provided Evexta Bio with valuable input on various aspects of rupitasertib development, including CMC, preclinical and clinical topics, enabling the company to proceed with the Phase 2 study in advanced breast cancer.
  • Recent preclinical studies in ESR1mt breast cancer models have shown compelling synergistic effects of rupitasertib administered in combination with elacestrant.
  • These data support the preliminary clinical efficacy observed in the Phase 1 study and warrant the development of rupitasertib in ESR1mt ER+ HER2- advanced breast cancer patients.
  • In addition, S6K has been shown to be closely associated with the emergence of cancer resistance, particularly in breast cancer, through ER modulation.

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

Retrieved on: 
금요일, 4월 19, 2024
Mutation, MBC, KOL, Therapy, Patient, Neoplasm, Harvard Medical School, MD Anderson Cancer Center, Massachusetts General Hospital, Breast cancer, ESR1, Pharmaceutical industry

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m.

Key Points: 
  • COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m.
  • ET, featuring Senthil Damodaran, M.D., Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D. (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.
  • The event will focus on the company's ELAINE (Evaluating Lasofoxifene in ESR1 Mutations) studies investigating lasofoxifene in patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an estrogen receptor 1 (ESR1) mutation.
  • A live question and answer session will follow the formal presentations.

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
금요일, 4월 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.